With an appearance of recombinant tissue plasminogen activator (rtPA) and new devises to retrieve a clot, the management of stroke therapy is changing. However, the number of people who can get this benefit is still very few. To establish new brain protective therapy is urgent. In this article we will display our recent trials. We applied a protein transduction technology using the artificial super anti-apoptotic FNK protein fused with a protein-transductiondomain peptide (PTD-FNK), which showed significant reduction of infarct volume. Next was the application of anticonvulsive drug valproic acid (VPA) to cerebral ischemia. Injecting VPA showed significant protective effect by reducing oxidative stress and inflammatory changes. 
